How the DA subtype of Wilms tumour resists chemotherapy
Researchers suggest that DA histology slowly emerges by accumulating burdens of DNA damage and copy number aberrations.
List view / Grid view
Researchers suggest that DA histology slowly emerges by accumulating burdens of DNA damage and copy number aberrations.
Learn about the different types of multiplexed imaging available, as well as their applications, benefits and disadvantages.
This app note explores a groundbreaking multiplex immunodetection approach to identify cancer stem cell niches within hepatocellular carcinoma (HCC).
A novel technology can reduce tumour sizes significantly and improve treatment efficacy when used with existing immunotherapy.
For the first time, mitochondrial DNA mutations could be used with immunotherapy to increase the chances of successful treatments.
The Ku70 protein prevents cancer cells from becoming more aggressive and metastasising. It could also be used as an immune biomarker.
Download this report to discover more about human derived induced pluripotent stem cells (hiPSCs), the suitability of NK cells for cancer therapy and the latest research into Alzheimer’s disease.
Scientists demonstrate how disrupting the Cx26 molecular complex in triple-negative breast cancer cells slowed tumour growth.
Researchers observed significant upregulation of Siglec-15 in the tumour microenvironment in bone tumour samples from breast cancer patients.
Researchers discover that blocking PD-L2 in senescent cells increases the efficacy of chemotherapy in mouse models.
PLK4 inhibition could be a novel therapeutic for an acute myeloid leukaemia subtype carrying the TP53 mutation.
A patient-specific organ-on-a-chip model of cholangiocarcinoma, with its tumour microenvironment, helps to predict therapy response.
Inhibiting mTOR signalling and neutralising mtROS suppressed MCC-PD-1-mediated tumour proliferation in mice.
In this exclusive interview, Dr Espen Basmo Ellingsen, a luminary in cancer immunology, provides insights into the anticipated breakthroughs, collaborative endeavours, and personalised strategies that promise to elevate the effectiveness and durability of immuno-oncology interventions.
Inhibition of FAM3C expression in cancer-associated adipocytes during early tumour development holds promise as a novel treatment approach.